FDA approves lisocabtagene maraleucel (liso-cel or JCAR-017) a CAR-T cell therapy for relapsed or refractory large B-cell lymphoma
Hopefully the next approval will be for CLL patients, but there is still much work to be done in clinical trials to get us across that finish line.
CAR-T therapy should and will be a significant part of CLL treatment, hopefully in the not too distant future
For now, our friends with a sister B cell lymphoma, Mantle Cell Lymphoma, have reason to celebrate.
Here is the link to FDA’ s official Press Release.
Related posts
